ÉöÔ´ÐÔϸ°ûÒò×Ó´Ùºìϸ°ûÉú³ÉËØ¶Ô¼±ÐÔ¼¹ËèËðÉË´óÊóϸ°ûµòÍöµÄÓ°Ïì**¡ï
ÿ
³ÂÊçÇ¿1£¬ÐìÓÖ¼Ñ1£¬Óá ³¿1£¬ºÂÑåÃ÷1£¬ÕÅÕñ¶«1£¬¹ËÓÀƽ2
¿ÎÌâ±³¾°£º2002Äênature medline·¢±íÌâΪErythropoietin styikes a new cord ÎÄÕÂ,±¨µÀ²ûÊöÁË´Ùºìϸ°ûÉú³ÉËØ×÷ΪһÖÖеÄÉñ¾±£»¤Òò×ӵĿÉÄÜ»úÖÆºÍÓ¦ÓÃǰ¾°¡£´Ëºó´óÁ¿ÊµÑé̽Ë÷´Ùºìϸ°ûÉú³ÉËØÉñ¾±£»¤×÷ÓõĿÉÄÜ»úÖÆ£¬²¢¶ÔÆä¿Éͨ¹ý¶àÖÖ;¾¶À´ÒÖÖÆ¼Ì·¢ÐÔ¼¹ËèËðÉËÒÑÓгõ²½µÄÈÏʶ¡£
Ó¦ÓÃÒªµã£ºÔçÆÚÓ¦ÓÃÍâÔ´ÐÔ´Ùºìϸ°ûÉú³ÉËØ¶Ô¼¹Ëè²»ÍêÈ«ËðÉ˺óÒýÆðµÄÉñ¾Ô˶¯¹¦ÄÜË𺦾ßÓб£»¤×÷ÓÃ,´ËÖÖ±£»¤×÷ÓÃÓë´Ùºìϸ°ûÉú³ÉËØÄܹ»¼õÉÙÉñ¾Ï¸°ûµòÍöÓйء£
Ïà¹ØÁ´½Ó£ºÒÑÓеÄÑо¿´ó¶àͨ¹ý¾²Âö×¢Éä»ò¸¹Ç»×¢Éä¸øÒ©Í¾¾¶¹Û²ì´Ùºìϸ°ûÉú³ÉËØ¶Ô¼±ÐÔ¼¹ËèËðÉ˵ı£»¤×÷Óá£ÏÖÔÚ¶ÔÓÚ¼¹ËèËðÉ˺óͨ¹ýӲĤÍâ;¾¶¾Ö²¿¸øÒ©µÄÖÎÁÆÐ§¹ûÖð½¥±»ÈÏʶ²¢Ó¦Óã¬ËäÈ»´ó¶àÓÃÀ´×¢ÉäÌÇÆ¤Öʼ¤ËØ¡£±¾ÊµÑé¼´²ÉÓÃӲĤÍâÇ»×¢Éä¸øÒ©µÄ·½Ê½À´¹Û²ì´Ùºìϸ°ûÉú³ÉËØ¶Ô¼±ÐÔ¼¹ËèËðÉ˵ÄÖÎÁÆÐ§¹û¡£
1ËÕÖÝ´óѧ¸½ÊôµÚ¶þÒ½Ôº¹Ç¿Æ£¬½ËÕÊ¡ËÕÖÝÊÐ 215004£»2ËÕÖÝ´óѧ»ù´¡Ò½Ñ§Ïµ²¡Àí½ÌÑÐÊÒ, ½ËÕÊ¡ËÕÖÝÊÐ
215123
³ÂÊçÇ¿¡ï£¬ÄУ¬1982ÄêÉú£¬É½¶«Ê¡ÁÙÒÊÊÐÈË£¬ºº×壬ËÕÖÝ´óѧÔÚ¶Á˶ʿ£¬Ò½Ê¦£¬Ö÷Òª´Óʼ¹Öù¼¹ËèËðÉ˵ÄÑо¿¡£
chenshuqiang_0@
yahoo.com.cn
ͨÐÅ×÷ÕߣºÐìÓּѣ¬²©Ê¿£¬Ö÷ÈÎҽʦ,½ÌÊÚ£¬ËÕÖÝ´óѧ¸½ÊôµÚ¶þÒ½Ôº¹Ç¿Æ£¬½ËÕÊ¡ËÕÖÝÊÐ 215004
xuyoujia@
medmail.com.cn
½ËÕÊ¡ÎÀÉúÌüҽѧ·¢Õ¹»ù½ð£¨H200346£©*£»ËÕÖÝÊÐÉç»á·¢Õ¹ÏîÄ¿»ù½ð£¨ssy0625£©*
ÕªÒª
Ä¿µÄ:´Ùºìϸ°ûÉú³ÉËØÎªÉöÔ´ÐÔϸ°ûÒò×Ó£¬ÔÚ´óÊó¼±ÐÔ¼¹ËèËðÉ˺ó¶Ô¼¹ËèÉñ¾¹¦ÄܾßÓб£»¤×÷Óá£ÊµÑéÄâÖ¤Ã÷²»Í¬Ê±¼äӲĤÍâÇ»×¢ÉäºóÆä¶Ô¼¹ËèÉñ¾Ï¸°ûµòÍöµÄÓ°Ïì¡£
·½·¨£ºÊµÑéÓÚ2007-01/04ÔÚËÕÖÝ´óѧ¸½ÊôµÚ¶þÒ½Ôº¶¯ÎïʵÑéÊÒÍê³É¡£¢ÙʵÑé²ÄÁÏ£ºÇå½à¼¶³ÉÄêÐÛÐÔSD´óÊó48Ö»£¬ÌåÖÊÁ¿(270 ¡À10) g£»ÊµÑéÓÃÈËÖØ×é´Ùºìϸ°ûÉú³ÉËØÎªÈÕ±¾÷è÷ëÆ¡¾ÆÖêʽ»áÉçÖÆÔ죬¹æ¸ñ3 000 IU /Ö§¡£¢ÚʵÑé·Ö×é¼°´¦Àí£º½«´óÊóËæ»ú·ÖΪÕý³£×é6Ö»£¬¼ÙÊÖÊõ×é6Ö»£¨½öÇгý×µ°å£©£¬ÉúÀíÑÎË®×é18Ö»£¬ÊµÑé×é18Ö»¡£°´¸ÄÁ¼Allen´ò»÷·¨½¨Á¢´óÊó¼¹Ëè²»ÍêÈ«ËðÉËÄ£ÐÍ¡£ÊµÑé×é·Ö±ðÓÚ´óÊó¼¹ËèËðÉ˺ó1£¬6£¬24 h£¨Ã¿¸öʱ¼äµã6Ö»£©£¬ÓÚӲĤÍâÇ»×¢ÉäÖØ×éÈË´Ùºìϸ°ûÉú³ÉËØ5 000 u/£¨kg¡¤bw£©£»ÉúÀíÑÎË®×éÓÚÏàͬʱ¼äÓèÒÔÏàͬÌå»ýÉúÀíÑÎË®¡£¢ÛʵÑéÆÀ¹À£ºÍ¨¹ý¶¯ÎïÉñ¾Ô˶¯¹¦ÄÜBBBÆÀ·Ö¼°Ð±°åÊÔÑéÆÀ¼ÛÉñ¾ËðÉ˳̶ȣ»ËÕľ¾«£ÒÁºìȾɫ·¨¹Û²ì×é֯ѧ¸Ä±ä£¬²¢²ÉÓÃÔλĩ¶Ë±ê¼Ç·¨±ê¼Ç·¨¼ì²â¼¹ËèÉñ¾Ï¸°ûµòÍöÊý¡£
½á¹û£º¢ÙÉñ¾ÐÐΪѧÆÀ·Ö£ºÕý³£×é¡¢¼ÙÊÖÊõ×é´óÊóË«ÏÂÖ«Ô˶¯¹¦ÄÜÕý³££»ÓëÉúÀíÑÎË®×éÏà±È,¼¹ËèËðÉ˺óʵÑé×é1,6¼°24 hÉñ¾Ô˶¯¹¦ÄÜÓиÄÉÆ£»Ð±°å½Ç¶È¼°BBBÆÀ·Ö¾ùÃ÷ÏÔÌá¸ß£¬²î±ðÓÐÏÔÖøÐÔÒâÒå(P < 0.05)¡£¢Ú×é֯ѧËÕľ¾«£ÒÁºìȾɫ½á¹û£ºÊµÑé×é×éÖ¯Ñ§ÆÆ»µ¸Ä±äÃ÷ÏÔ½ÏÉúÀíÑÎË®×éÇá¡£¢ÛµòÍöÉñ¾Ï¸°û¼°¼ÆÊý½á¹û£ºÊµÑé×é¼¹ËèÉñ¾Ï¸°ûµòÍöÖ¸Êý¾ùÃ÷ÏÔϽµ£¬²îÒìÓÐÏÔÖøÐÔ(P < 0.05)¡£
½áÂÛ£ºÔçÆÚÓ¦ÓÃÍâÔ´ÐÔ´Ùºìϸ°ûÉú³ÉËØ¶Ô¼¹Ëè²»ÍêÈ«ËðÉ˺óÒýÆðµÄÉñ¾Ô˶¯¹¦ÄÜË𺦾ßÓб£»¤×÷ÓÃ,ÄÜÃ÷ÏÔ¸ÄÉÆ¼¹ËèËðÉ˺óµÄÁÙ´²¹¦ÄܱíÏÖ¡£´ËÖÖ±£»¤×÷ÓÃÓë´Ùºìϸ°ûÉú³ÉËØÄܹ»ÒÖÖÆÉñ¾Ï¸°ûµòÍöÓйء£
¹Ø¼ü´Ê£º¼¹ËèËðÉË£¬ºìϸ°ûÉú³ÉËØ£¬ÖØ×飻ϸ°ûµòÍö£»×¢É䣬ӲĤÍ⣻×éÖ¯¹¹½¨
³ÂÊçÇ¿£¬ÐìÓּѣ¬Ó᳿£¬ºÂÑåÃ÷£¬ÕÅÕñ¶«£¬¹ËÓÀƽ.ÉöÔ´ÐÔϸ°ûÒò×Ó´Ùºìϸ°ûÉú³ÉËØ¶Ô¼±ÐÔ¼¹ËèËðÉË´óÊóϸ°ûµòÍöµÄÓ°Ïì[J].Öйú×éÖ¯¹¤³ÌÑо¿ÓëÁÙ´²¿µ¸´£¬2008£¬12(11):2034-2038 [www.zglckf.com/zglckf/ejournal/upfiles/08-11/11k-2034(ps).pdf]
ÖÐͼ·ÖÀàºÅ:R651.21
ÎÄÏ×±êʶÂë:A
ÎÄÕ±àºÅ:1673-8225
(2008)11-02034-05
ÊÕ¸åÈÕÆÚ£º2007-08-01
ÐÞ»ØÈÕÆÚ£º2007-09-19
(07-50-8-4258/W¡¤A)
Protective effect of erythropoietin on neurocyte apoptosis following experimental acute spinal cord injury in rats
Abstract
AIM:Erythropoietin, a cell factor produced by kidney, can protect spinal nerve from acute spine cord injury (SCI) in rat. The experiment explored the effects of erythropoietin on the apoptosis of neural cells.
METHODS: The experiment was performed in the animal laboratory of Second Affiliated Hospital of Soochow University from January to April 2007. ¢ÙForty-eight adult male Sprague-Dawley rats of (270¡À10) g were randomly divided into normal group (n =6), sham operation group (n =6) underwent laminectomy procedure only, saline group (n =18) and treatment groups (n =18). The SCI models were established using the improved Allen method. The rats in treatment group were epidurally injected with 5 000 u/kg body mass of recombinant human erythropoietin (Kirin Beer Company, Japan, 3 000 IU per piece) 1, 6, and 24 hours after injury respectively (6 animals at each time point). Control group received normal saline epidurally at the same time point. ¢ÛBehavioral evaluation of the rats was made 48 hours after trauma by using the Basso, Beattie, and Bresnahan (BBB) scoring system and Rivlin's tiltboard experiment; Hematoxylin and eosin (HE) staining was performed for histological observation after injury. Injured spinal cord tissues cells apoptosis were examined by the terminal deoxynucleotidal transferase-mediated dUTP-biotin nick end labeling (TUNEL) reaction.
RESULTS: ¢ÙNeuroethology evaluation: The both lower extremities of rats in normal group and sham operation group showed normal movement function. Compared to saline group, neuromotor function in rats after SCI was significantly improved in 1, 6 and 24 hours, and the angles of Rivlin's tiltboard experiment and the scores of BBB were significantly increased (P < 0.05). ¢ÚHE staining results suggested that the histological damage extent of the spine cord in treatment group was remarkably lessened compared with saline group. ¢ÛTUNEL staining: The number of TUNEL-positive cells was significantly decreased in the erythropoietin-treated rats (P < 0.05).
CONCLUSION: Early application of recombinant human erythropoietin can lessen the lesion of neuromotor function, and significantly improve the clinical function after SCI. The protection is partially due to the reduction of neural cell apoptosis.
Chen SQ, Xu YJ, Yu C, Hao YM, Zhang ZD, Gu YP.Protective effect of erythropoietin on neurocyte apoptosis following experimental acute spinal cord injury in rats.Zhongguo Zuzhi Gongcheng Yanjiu yu Linchuang Kangfu 2008;12(11):2034-2038(China) [www.zglckf.com/zglckf/ejournal/upfiles/08-11/11k-2034(ps).pdf]
0 ÒýÑÔ
¼¹ËèËðÉËÊǹǿƳ£¼ûµÄÑÏÖØ¼²»¼¡£ÈçºÎÓÐЧµÄÖÎÁÆÒ»Ö±ÊÇÀ§ÈÅҽѧ½çµÄÒ»´ó¿ÎÌâ¡£½üÄêÀ´·¢ÏÖ´Ùºìϸ°ûÉú³ÉËØ(erythropoietin, EPO) ¼´ÄÚÔ´ÐÔÔìѪÉú³¤Òò×Ó²»½öÓ°Ïìºìϵϸ°û£¬¶øÇÒÊÇÒ»Öֶ๦ÄܵÄÓªÑøÒò×Ó£¬¶ÔÖÐÊàÉñ¾ÓÐÁ¼ºÃµÄÉñ¾±£»¤×÷Ó㬲¢ÓÐÍû³ÉΪÖÎÁƼ¹ËèËðÉ˵ÄÒ»ÖÖÐÂÐÍÒ©Îï[1-3]¡£ÒÑÓÐÎÄÏ×±¨µÀÔÚ¼¹ËèËðÉ˵ÄʵÑéÑо¿Öз¢ÏÖ´Ùºìϸ°ûÉú³ÉËØ¿ÉÒÖÖÆ¼¹ËèËðÉ˺óÉñ¾Ï¸°ûµÄ¼Ì·¢ÐÔËðÉË£¬±£»¤ÊÜËðÉñ¾Ôª[4-6]£¬µ«´ó¶à²ÉÓø¹Ç»×¢Éä;¾¶¡£±¾ÊÔÑ齫²ÉÓÃÈËÖØ×é´Ùºìϸ°ûÉú³ÉËØÓ²Ä¤ÍâÇ»×¢Éä·½·¨£¬Ì½ÌÖ´Ùºìϸ°ûÉú³ÉËØÔÚ¼¹ËèËðÉ˺ó¶ÔËðÉ˼¹ËèÉñ¾µÄÉñ¾±£»¤×÷Óá£
1 ²ÄÁϺͷ½·¨
Éè¼Æ£ºËæ»ú¶ÔÕÕ¶¯ÎïʵÑé¡£
µ¥Î»£ºËÕÖÝ´óѧ¸½ÊôµÚ¶þÒ½Ôº¹Ç¿Æ¡£
²ÄÁÏ£ºÊµÑéÓÚ2007-1/04ÔÚËÕÖÝ´óѧ¸½ÊôµÚ¶þÒ½Ôº¶¯ÎïʵÑéÊÒ(BSL-2)Íê³É¡£Çå½à¼¶³ÉÄêÐÛÐÔSD´óÊó48Ö» (ËÕÖÝ´óѧҽѧԺʵÑ鶯ÎïÖÐÐÄÌṩ£¬Ðí¿ÉÖ¤ºÅ£ºFYXK ËÕ 2007- 0035)£¬ÌåÖÊÁ¿260~285 g£¬Æ½¾ù270.6 g¡£ÈËÖØ×é´Ùºìϸ°ûÉú³ÉËØ(ÈÕ±¾÷è÷ëÆ¡¾ÆÖêʽ»áÉçÖÆÔì,¹æ¸ñ3 000 IU /Ö§)¡£ÊµÑé¹ý³ÌÖжԶ¯Îï´¦Ö÷ûºÏ¶¯ÎïÂ×Àíѧ±ê×¼¡£
Éè¼Æ¡¢ÊµÊ©¡¢ÆÀ¹ÀÕߣº±¾ÊµÑéÓɵڶþ×÷ÕßÉè¼Æ£¬µÚÒ»¡¢µÚÈý¡¢µÚËÄ×÷ÕßʵʩºÍÆÀ¹À£¬¾ùÊܹýÏàÓ¦µÄÅàѵ¡£
¼¼Êõ·Ïߣº
½¨Á¢¼¹ËèËðÉËÄ£Ðͼ°Ó²Ä¤ÍâÖùÜÊõ£º²ÉÓøÄÁ¼Allen´ò»÷·¨[7]ÖÆ×÷´óÊó¼¹ËèËðÉËÄ£ÐÍ£¬ÊÖÊõÑϸñÔÚÎÞ¾úÌõ¼þÏÂÍê³É¡£´óÊóÓÃ40 g/L Ë®ºÏÂÈÈ©(10 mL/ kg) ¸¹Ç»×¢ÉäÂé×í£¬±¸Æ¤ºó£¬¸©ÎÔλ¹Ì¶¨£¬Ïû¶¾£¬ÆÌ¸ÇÎÞ¾ú½íµ¥¡£°´ÕÕNystrom·¨[8]£¬ÒÔT12ΪÖÐÐÄ£¬ÇпªÆ¤·ôºÍ¼¡È⣬³¤Ô¼2 cm£¬ÏÔ¶T11~13¼¬Í»ºÍ×µ°å£¬Ò§³ýT12¼¬Í»ºÍ×µ°å£¬ÒÔT12¼¹ËèΪÖÐÐÄÏÔ¶´óСΪ3 mm¡Á4 mmµÄ´ò»÷Çø¡£ÔÚӲĤ±íÃæµæÒ»Çú¶ÈÓë¼¹Ëè±íÃæÒ»ÖµÄËÜÁÏµæÆ¬£¬ÓÃÖ±¾¶2.5 mm¡¢ÖØ10 gµÄÔ²Öù×´½ðÊô°ôÔÚϸ²£Á§¹ÜµÄÒýµ¼Ï´Ó7 cm¸ß´¦´¹Ö±ÂäÏ´ò»÷£¬Ôì³ÉÒÔT12ΪÖÐÐĵļ¹Ëè¼±ÐÔ´ìÉË[ÖÂÉËÁ¦Îª70 (g¡¤cm)]¡£
ʵÑé·Ö×飺²ÉÓÃËæ»úÊý×Ö±í·¨·ÖΪÕý³£×é6Ö»£¬½ö¸øÓëÂé×í£»¼ÙÊÖÊõ×é6Ö»£¬Âé×íºóÐÐ×µ°åÇгýÊõ£»ÉúÀíÑÎË®×é18Ö»£¬½¨Á¢¼¹ËèËðÉËÄ£ÐÍ£¬Ó²Ä¤ÍâÇ»×¢ÉäÉúÀíÑÎË®£»ÊµÑé×é18Ö»£¬½¨Á¢¼¹ËèËðÉËÄ£ÐÍ£¬Ó²Ä¤ÍâÇ»×¢ÉäÖØ×éÈË´Ùºìϸ°ûÉú³ÉËØ5 000 IU/kg¡£
ӲĤÍâÖùÜÊõ£º´óÊó¼¹ËèËðÉËÄ£Ðͽ¨Á¢ºó½«³¤Ô¼6 cm µÄPE-10¾ÛÒÒÏ©¹Ü(Íâ¾¶0.6 mm£¬ÄÚ¾¶0.3 mm£¬Äþ²¨°²À´¿Æ¼¼¹«Ë¾)Ïò´óÊóβ¶Ë²åÈëӲĤÍâǻԼ0.5 cm£¬ÑÏÃÜ·ìºÏÉ˿ڼ¡Èâ²ã²¢¹Ì¶¨µ¼¹Ü£¬´ÓƤ·ôÇпÚÒ»²àÒý³ö£¬·ìºÏÉ˿ںóÓÃÒÒ´¼µÆÉÕׯĩ¶Ë·â±Õµ¼¹Ü¡£ËðÉ˺óÿÌì3´ÎÈ˹¤°´Ñ¹°òë×ÅÅÄò¡£¼ÙÊÖÊõ×é½öÐÐ×µ°åÇгý¡£ÊµÑé¸÷×é´óÊó¾ù¼¡×¢ÇàÃ¹ËØ1´Î/d£¬·ÖÁýËÇÑø¡£
ÖØ×éÈË´Ùºìϸ°ûÉú³ÉËØ¸ÉÔ¤·½·¨£º·Ö±ðÓÚ´óÊó¼¹ËèËðÉ˺ó1£¬6£¬24 h(ÿ¸öʱ¼äµã6Ö»)£¬¼ô³ýµ¼¹ÜÄ©¶Ë£¬ÓÃ1 mLÎÞ¾úÒȵºËØ×¢ÉäÆ÷(Õë¼â29 G)£¬Á¬½Óµ¼¹Ü×¢Ò©£¬»ºÂýÍÆ×¢Ô¼30 s¡£ÊµÑé×éÓèÒÔÖØ×éÈË´Ùºìϸ°ûÉú³ÉËØ£¬5 000 u/(kg¡¤bw)£»ÉúÀíÑÎË®×éÓÚÏàͬʱ¼äÓèÒÔÏàͬÌå»ýÉúÀíÑÎË®¡£
Éñ¾ÐÐΪѧÆÀ·Ö£º²ÉÓøÄÁ¼Ð±°åʵÑéºÍBBB·Ö¼¶ÆÀ·Ö·¨[9]ÓÚÊõǰ¡¢Êõºó1 hºÍÊõºó48 h˫ä·¨ÆÀ¼Û¸÷×é´óÊóË«²àºóÖ«Ô˶¯¹¦ÄÜ¡£
¸ÄÁ¼Ð±°åʵÑ飺б°åµÄÐ±ÃæÇãб½Ç¶ÈΪ¿Éµ÷¿ØÐÍ¡£ÓÉ2Ãû·Ç±¾¿ÎÌâ×éµÄʵÑéÈËÔ±·Ö±ð¹Û²ì, ¼Ç¼ºóÈ¡Æä¾ùÖµ¡£¢ÙËùÓдóÊó¾ùÓÚÊõǰÐÐб°åʵÑéУÕý²¢É¸Ñ¡¡£¼Ç¼¸÷×é´óÊóά³Öƽºâ5 sʱб°åµÄ×î´ó½Ç¶È¡£¢ÚʵÑé×é¡¢ÉúÀíÑÎË®×é¡¢¼ÙÊÖ
Êõ×é·Ö±ðÓÚÊõºó1 hÍêÈ«ÇåÐѺóÓëÊõºó24£¬48 h²âÁ¿´óÊóά³Öƽºâ5 sʱб°åµÄ×î´ó½Ç¶È¡£
BBB·Ö¼¶ÆÀ·Ö·¨£º½«´óÊóÖÃÓÚ¿ª·ÅµÄ»·¾³ÖУ¬ÓÐÁ½ÃûÊìÏ¤ÕÆÎÕBBBÆÀ·Ö±ê×¼µÄ·Ç±¾ÊµÑéÈËÔ±¶ÀÁ¢¹Û²ì4 min²¢ÆÀ·Ö¡£BBB·Ö¼¶ÆÀ·Ö·¨¸ù¾Ý¼¹ËèËðÉ˺ó¶¯ÎïºóÖ«µÄÔ˶¯ÄÜÁ¦·ÖΪ21¸öµÈ¼¶¼´×î¸ß·ÖΪ21·Ö¡£Ö÷Òª¹Û²ì£ººóÖ«¹Ø½ÚµÄ»î¶¯ÄÜÁ¦£¬ÄÜ·ñ¸ºÖؽÅÕÆÕ¾Á¢,ÓÐÎÞǰºó֫е÷Ô˶¯£¬ºó½ÅצµÄÉìÕ¹¼°×ŵØÇé¿öºÍβ°ÍµÄƽºâ¡£ÆÀ·Öȡ˫ºóÖ«ÆÀ·ÖµÄ¾ùÖµ¡£
Ôλĩ¶Ë±ê¼Ç·¨¼ì²âµòÍöÉñ¾Ï¸°ûȾɫ£º²ÉÓÃÔλϸ°ûËÀÍö¼ì²âÊÔ¼ÁºÐ(Î人²©Ê¿µÂ¹«Ë¾)¡£Ö÷Òª²½Ö裺ʯÀ¯ÇÐÆ¬ÍÑÀ¯ºÍË®»¯ºó£¬Ë«ÕôË®³åÏ´£¬0.05 mol/LÁ×ËáÑλº³åÒº(pH 7.6) ³åÏ´£»20 mg/L µ°°×øKÈÜÓÚ10 mmol /L Tris -HCl ÒºÖÐ(pH 7.4)£¬37 ¡æ ˮԡ²ÛÄÚÏû»¯30 min£¬Á×ËáÑλº³åҺϴ5 min¡Á3 ´Î;µÎ¼ÓÔλĩ¶Ë±ê¼Ç·´Ó¦Òº(TdT øÈÜÒººÍµØ¸ßÐÁ±ê¼ÇµÄºËÜÕËá»ìºÏÎïÈÜÒºÓÚʹÓÃǰ°´1¡Ã1 ±ÈÀý»ìºÏ)¡£Ã¿ÕÅÇÐÆ¬50 ¦Ìm£¬37 ¡æ ·õÓý60 min¡£Á×ËáÑλº³åÒººó¼îÐÔÁ×Ëáøת»»Òº37 ¡æ ·õÓý30 min¡£Á×ËáÑλº³åÒº³åÏ´ºó,NBTPBCIPÏÔÉ«5~15 min£»Á×ËáÑλº³åÒº³åÏ´ºó,¸´È¾¡¢ÍÑË®¡¢ÖÐÐÔÊ÷½º·â¹Ì¡£
µòÍöϸ°û¼ÆÊý£ºÔÚÉ˺ó48 hÈ¡²Ä£¬Ã¿¸ö±ê±¾È¡ËðÉËÖÐÐļ°Í·Î²Á½¶Ë¹²3ÕÅÇÐÆ¬£¬²ÉÓÃOlympusBX60ÏÔ΢¾µË«Ã¤·¨½øÐоµ¼ì£¬¹Û²ì´óÊó¼±ÐÔ¼¹ËèËðÉ˺óµòÍöÉñ¾Ï¸°û¼°ÆäÏà¹Øµ°°×µÄ±í´ïÇé¿ö¡£ÓÉ2Ãû·Ç±¾¿ÎÌâ×é²¢ÇÒÊìϤµòÍöϸ°ûÐÎ̬µÄʵÑéÈËÔ±Ôڸ߱¶ÏÔ΢¾µÏÂËæ»úÑ¡Ôñ3¸ö²»ÖصþÊÓÒ°¹Û²ìͳ¼ÆµòÍöϸ°ûÊý¡£
Ö÷Òª¹Û²ìÖ¸±ê£º¢Ù¸÷×é´óÊóÉñ¾ÐÐΪѧÆÀ·Ö¡£¢Ú×é֯ѧËÕľ¾«£ÒÁºìȾɫ½á¹û¡£¢ÛµòÍöÉñ¾Ï¸°û¼ÆÊý¡£
ͳ¼ÆÑ§·½·¨£ºÊµÑéÊý¾ÝÒÔ_x¡Às±íʾ£¬ÓɵÚÒ»×÷Õß²ÉÓÃSPSS 10.0ͳ¼ÆÈí¼þ½øÐз½²î·ÖÎöºÍÁ½Ñù±¾Åä¶Ôt ¼ìÑ飬P < 0.05 Ϊ²îÒìÓÐÏÔÖøÐÔÒâÒå¡£
2 ½á¹û
2.1 ʵÑ鶯ÊýÊýÁ¿·ÖÎö ʵÑéÑ¡ÓôóÊó48Ö»£¬ÊµÑé¹ý³ÌÖÐÎÞÍÑʧ£¬È«²¿½øÈë½á¹û·ÖÎö¡£
2.2 ¸÷×é´óÊóÉñ¾ÐÐΪѧÆÀ·Ö б°åʵÑ飺Õý³£×éÒÔ¼°ÊõǰµÄ¼ÙÊÖÊõ×é¡¢ÉúÀíÑÎË®×éÓëʵÑé×é´óÊóб°åʵÑé½Ç¶ÈΪ51¡ã~55¡ã£»ÉúÀíÑÎË®×éÓëʵÑé×éÊõºó1 h´óÊóÍêÈ«ÇåÐѺóб°åÊÔÑé½Ç¶ÈÔÚ27¡ã~32¡ãÖ®¼ä£»ÔÚÊõºó 48 h£¬¸÷×é´óÊóб°åʵÑé½Ç¶È¾ù½ÏǰÌá¸ß£»Ð±°åʵÑé½Ç¶ÈʵÑé×éÓëͬÆÚÉúÀíÑÎË®×éÏà±È¾ùÃ÷ÏÔÌá¸ß£¬²îÒì¾ùÓÐÏÔÖøÐÔ£¨P < 0.05£©£¬×é¼ä±È½Ï²îÒìÎÞͳ¼ÆÑ§ÒâÒå¡£¼ûͼ1¡£
BBB·Ö¼¶ÆÀ·Ö£ºÕý³£×é¡¢¼ÙÊÖÊõ×é´óÊóË«ÏÂÖ«Ô˶¯¹¦ÄÜÕý³£¾ùΪ21·Ö¡£ÉúÀíÑÎË®×顢ʵÑé×é´óÊóÊõºó1 hʱºóÖ«¾ù³Ê²»Í¬³Ì¶È³Ú»ºÐÔ̱»¾£¬BBBÆÀ·ÖÔÚ2~4·ÖÖ®¼ä£¬½öÓÐ΢СµÄÏÞÓÚ÷Å¡¢Ï¥¹Ø½ÚµÄ·Ç·´ÉäÐÔÔ˶¯£»Êõºó48 h¸÷×éBBB·ÖÖµ¾ùÓÐÌá¸ß¡£½ÓÊÜÖØ×éÈË´Ùºìϸ°ûÉú³ÉËØ¸ÉÔ¤µÄʵÑé×é´óÊóÔÚÊõºó48 hºóÖ«³öÏÖ÷Å¡¢Ï¥¡¢¾àСÍȹؽڣ¨õ׹ؽڣ©²¿·Ö×ÔÖ÷»î¶¯£¬Õë´Ì¼¤Óз´Ó¦£¬µ«²»ÄܶԿ¹ÖØÁ¦£¬Å¼¶û¿ÉÓнű³×ŵػ£»ÊµÑé×é¾ù½ÏͬÆÚÉúÀíÑÎË®×éÓÐÃ÷ÏÔµÄÌá¸ß£¬²îÒìÓÐÏÔÖøÒâÒ壨P < 0.05£©¡£¼ûͼ2¡£
2.3 ´óÊó¼¹Ëè×é֯ѧËÕľ¾«-ÒÁºìȾɫ½á¹û Õý³£×é¼°¼ÙÊÖÊõ×é¼¹Ëè×éÖ¯»Ò°×ÖʽçÏÞÇå³þ£¬»ÒÖÊÄÚÉñ¾Ï¸°ûÌå´ó£¬ºËÈÊÇåÎú£¬°×ÖÊÄÚÉñ¾ÏËάÅÅÁÐÖÂÃÜÓÐÐò£¨¼ûͼ3£©¡£ÔÚÄ£ÐÍÖÆ×÷ʱ£¬¼´¿É¼ûËðÉ˼¹Ëè¾Ö²¿³öѪÖ×ÕÍ¡£ËÕľ¾«£ÒÁºìȾɫÇÐÆ¬¹â¾µÏ¿ɼûËðÉ˶ÎÓй㷺³öѪ£¬¼¹Ëè½á¹¹ÆÆ»µ£¬²¢ÓÐÑ×֢ϸ°û½þÈó£¬Ãæ»ý½Ïʵ¼Ê´ò»÷ËðÉËÃæ»ýÀ©´ó¡£ËðÉËÖÐÐIJ¿Î»ÓдóÁ¿µÄÉñ¾Ï¸°ûÈܽâËÀÍö£¬³öѪ»µËÀÇøÒ²Öð½¥±»¿ÕÅÝ´úÌæ£¬ÐγɴóÁ¿µÄ¿ÕÅÝÇø£¬½á¹¹É¢ÂÒ£¬°×ÖÊÖпɼûÖ×ÕÍÖáÍ»ºÍ´óÁ¿¿ÕÅÝ£¬²¿·ÖÉñ¾ÔªÄáÊÏÌåÏûʧ¡£»ÒÖÊÖнö´æÉÙÁ¿Éñ¾Ôª£¬Ö÷ҪλÓÚºó½Ç¡£²¿·ÖÉñ¾Ï¸°û¿É¼ûºË¹ÌËõ¡£´Ùºìϸ°ûÉú³ÉËØÊµÑé×é¾µÏÂÒ²¿É¼û´ò»÷ÇøÓгöѪ»µËÀ£¬µ«¼¹Ëè½á¹¹µÄÆÆ»µ³Ì¶È½ÏÉúÀíÑÎË®×éÇᣬ¿ÕÅÝÇøÃ÷ÏÔÉÙÓÚÉúÀíÑÎË®×é£¬ÆÆ»µÃæ»ýÒ²½ÏÉúÀíÑÎË®×éС¡£(¼ûͼ4£¬Í¼5)¡£
2.4 ¸÷×é´óÊóµòÍöÉñ¾Ï¸°û¹Û²ì¼°¼ÆÊý Ôλĩ¶Ë±ê¼Ç·¨±ê¼ÇµÄÑôÐÔϸ°û°ûºË³ÊרºÚÉ«£¬Õý³£×é¼°¼ÙÊÖÊý×é½ö¼ûżȾϸ°û,ÉúÀíÑÎË®×é¿É¼û´óÁ¿ÑôÐÔϸ°û±í´ï£¬°×Öʼ°»ÒÖÊÖоù¿É¼û£¬ÒÔ°×ÖÊÖÐΪÖ÷£ºÑôÐÔÉñ¾ÔªÏ¸°ûΪºË³ÊÉîºÖÉ«£¬°û½¬³Êרɫ£»ÑôÐÔ½ÇÖÊϸ°û½ÏС£¬³ÊÉîºÖÉ«µã×´£¨¼ûͼ6£©¡£ ÉúÀíÑÎË®×é1£¬6£¬24 hµòÍöϸ°ûÊýÁ¿²îÒì²»ÊǺܴó¡£ÓëÉúÀíÑÎË®×é±È½Ï£¬ÊµÑé×é1£¬6£¬24 h×éÉñ¾ÔªºÍÉÙÍ»½ºÖÊϸ°ûµÄÔλĩ¶Ë±ê¼Ç·¨ÑôÐÔϸ°ûÊýÃ÷ÏÔ¼õÉÙ£¨¼ûͼ7£©£¬²îÒìÓÐÏÔÖøÐÔÒâÒå(P < 0.05)¡£¼û±í1¡£

3 ÌÖÂÛ
1911ÄêAllenÊ×ÏȽ«¼¹ËèËðÉË·ÖΪԷ¢ÐÔËðÉ˺ͼ̷¢ÐÔËðÉËÁ½¸ö½×¶Î¡£½üÄêÀ´Ëæ×ÅÑо¿µÄÉîÈë¶Ô¼¹ËèËðÉ˵ľßÌå»úÖÆÓÐÁ˸üÃ÷È·¸üϸÖµÄÈÏʶ£¬µ«ÈÔ½«ÆäÃèÊöΪһ¸öÔ·¢ÐԺͼ̷¢ÐÔÁ½¸öËðÉ˽׶εĹý³Ì [10-12]¡£¼¹ËèËðÉ˵Ä×îÖÕËðÉ˳̶Ȳ»½öÈ¡¾öÓÚÔ·¢ÐÔËðÉ˵ij̶ȣ¬¸üÈ¡¾öÓڼ̷¢ÐÔËðÉËÔì³ÉµÄÉñ¾Ï¸°ûËÀÍöÒÔ¼°¼¹ËèÖÐÑë»ÒÖʵĿն´»¯³Ì¶È£¬ËùÒÔÔ¤·À¼Ì·¢ËðÉËÊÇÔçÆÚÖÎÁƵĹؼü¡£¼¹ËèËðÉË·¢Éúºó£¬ËðÉËÇø»á¼Ì·¢Ò»ÏµÁеÄÉñ¾Éú»¯¡¢Î¢Ñ»·Ê§µ÷¼°Ñ×Ö¢·´Ó¦£¬ÒýÆð´óÁ¿²¡ÀíÐÔµÄϸ°ûµòÍö·¢Éú¡£
×î½üµÄÑо¿ÖУ¬´Ùºìϸ°ûÉú³ÉËØÊÇÒ»ÖÖµ÷½Úºìϸ°ûÉú³ÉµÄÉöÔ´ÐÔϸ°ûÒò×Ó£¬±»·¢ÏÖ¶ÔÖÐÊàÉñ¾ÓÐÃ÷ÏÔµÄÉñ¾±£»¤×÷ÓÃ[1-3£¬13]¡£ÕâÖÖÒò×Ó±»·¢ÏÖÓкܶà×÷Ó㺰üÀ¨µ÷½Ú΢ѻ·µÄ×÷Óã¬ÒÖÖÆµòÍö¼õÇáÑ×Ö¢·´Ó¦£¬¿¹Ñõ»¯×÷Ó㬵÷½Úϸ°ûÐË·ÜÐÔºÍÉñ¾¸Éϸ°û·Ö»¯ÔöÖ³µÈ¡£ÔÚ´óÊó¼¹ËèËðÉËÄ£Ð͵ÄʵÑéÖУ¬Ò»Ð©×÷Õß±¨µÀÔÚ¼¹ËèȱѪ»ò´´ÉËÖдٺìϸ°ûÉú³ÉËØÄܹ»ÒÖÖÆËðÉ˵ÄÀ©´óºÍ·¢Õ¹£¬ÏÔÖøµÄ´Ù¾Éñ¾¹¦ÄܵĻָ´£¬ÄÜÃ÷ÏÔÔ¤ºó[14-15]¡£´Ùºìϸ°ûÉú³ÉËØÍ¨¹ýÓëÌØÒìÐÔ´Ùºìϸ°ûÉú³ÉËØÊÜÌå½áºÏ£¬¼¤»îÏàÓ¦µÄÐźÅתµ¼Í¾¾¶·¢»ÓÆäÉúÎïѧЧӦ[14]¡£
³ý»µËÀÍ⣬ϸ°ûµòÍöÊdzٷ¢ÐÔ¼¹ËèËðÉ˺óÉñ¾Ï¸°ûËÀÍöµÄÖØÒª·½Ê½£¬½üÄêÀ´Ðí¶àʵÑéÑо¿ÒÑ֤ʵ[16-17]¡£µ÷ÍöËðÉ˱»ÈÏΪÊǼ±ÐÔ¼¹ËèËðÉ˺óÉñ¾¹¦ÄܸÄÉÆµÄÖØÒªÍ¾¾¶¡£LiuµÈ[18] 1997Ä걨¸æ·¢ÏÖÔÚ¼¹ËèËðÉËAllen´ò»÷Ä£ÐÍÖÐËðÉË·¶Î§Éñ¾Ï¸°ûµòÍöÔÚ»ÒÖÊÇøÉ˺ó6 h¼´ÓгöÏÖµ«ÊýÁ¿½ÏÉÙ£¬24 hÔö¶à£¬48~72 hά³ÖÔÚ×î¸ßˮƽ£»°×ÖÊÇø6 h¿É¼û£¬48~72 hά³ÖÔÚ×î¸ßˮƽ¡£ÏÈǰµÄÑо¿½á¹ûÓë´ËÏà·ûºÏ[19]¡£ËùÒÔ±¾ÊµÑéѡȡ48 h´¦ËÀ£¬¼´ÊÇÔÚ´óÊó¼¹ËèËðÉ˺óµòÍö·¢ÉúµÄ¸ß·åÆÚ»ñÈ¡±ê±¾£¬À´¹Û²ì¸÷×éµÄ±ä»¯£¬ÕâÑù¸üÄÜ׼ȷ¶øÃô¸ÐµÄ²â¶¨µòÍö±í´ïµÄ²îÒìÐÔ¡£
ËäÈ»ÔÚ¼¹ËèËðÉËÖдٺìϸ°ûÉú³ÉËØµÄ¾ßÌåÉñ¾±£»¤×÷ÓõĻúÖÆ»¹²»Çå³þ£¬µ«Ñо¿±íÃ÷´Ùºìϸ°ûÉú³ÉËØÔڼ̷¢ÐÔËðÉËÖжԵòÍöÓÐ×ÅÏÔÖøµÄÓ°ÏìÁ¦[20]¡£±¾ÊµÑéͨ¹ý²»Í¬Ê±¼äÓ¦Óôٺìϸ°ûÉú³ÉËØ¸ÉÔ¤¼¹ËèËðÉË£¬ÊÔͼ¶ÔÕâ·½Ãæ½øÐÐ̽Ë÷¡£ÒÔÍùµÄÑо¿¶à²ÉÓø¹Ç»»ò¾²Âö×¢Éä;¾¶£¬µ«Ñо¿±íÃ÷Ö»ÓÐÔÚ´Ùºìϸ°ûÉú³ÉËØ×¢ÉäÁ¿´ï500 IU/kgÒÔÉϲŶԼ¹ËèËðÉËÓÐÖÎÁÆÐ§¹û[21]¡£Ó²Ä¤Íâ×¢ÉäÒ²ÊÇÁÙ´²¸øÒ©µÄÒ»ÖÖ³£¹æÍ¾¾¶£¬Ö»ÊÇÆä²Ù×÷ÄѶȽϴó²»ÈçÉÏÃæÁ½ÖÖ¼òµ¥Ò×ÐУ¬µ«ÏÖÔÚÖ±½Ó²ÉÓÃÒ©ÎïÀ´Ô¤·À»òÖÎÁƼ¹ËèËðÉËÒÑÖð½¥Ô½À´Ô½¶àµÄÓ¦ÓÃ[22]£¬Âé×í¿ÆÓ¦ÓõÄ×îΪ¹ã·º£¬Ó²Ä¤Íâ×¢Éä¿ÉÒÔʹҩÎïÖ±½Ó×÷ÓÃÓÚËðÉ˾ֲ¿£¬ÖÎÁÆ×÷Óøü¿ì¸üÖ±½Ó£¬¼õÉÙÒ©ÎïµÄʹÓüÁÁ¿£¬¿É½µµÍ´Ùºìϸ°ûÉú³ÉËØ¿ÉÄܵĸ±×÷Óá£ÄÔȱѪȱÑõËðÉËÖ±½Ó×¢Éä´Ùºìϸ°ûÉú³ÉËØÈë´óÄÔ¿ÉÒÔ¼õÇáÉñ¾×éÖ¯µÄËðÉË[23]¡£±¾ÊµÑé²ÉÓÃӲĤÍâ;¾¶Ó¦Óôٺìϸ°ûÉú³ÉËØ¸ÉÔ¤£¬³õ²½Ì½ÌÖ´Ë;¾¶Ó¦ÓõÄЧ¹û¡£
±¾ÊµÑé½á¹ûÔÙ´Î֤ʵ¼¹ËèËðÉ˺ó¼¹Ëè×éÖ¯ÖÐÉñ¾Ï¸°ûµòÍö¹ã·º´æÔÚ, ÔÚ»ÒÖʺͰ×ÖÊÖоù¼ì²âµ½ÑôÐÔϸ°û, °×ÖÊÖÐΪÖ÷¡£Ó¦ÓÃÍâÔ´ÐÔ´Ùºìϸ°ûÉú³ÉËØ¸ÉÔ¤¿ÉÒÔÃ÷ÏÔ¼Ó¿ìÉñ¾¹¦Äָܻ´£¬¸ÄÉÆÁÙ´²Ô¤ºó£»Éñ¾Ï¸°ûµòÍöµÄ·¢ÉúÃ÷ÏÔ¼õÉÙ¡£Í¨¹ýб°åÊÔÑéºÍBBBÆÀ·Ö½á¹û±íÃ÷£¬¸øÒ©Ê±¼äÔ½Ô磬¼¹Ëèǰ½ÇÔ˶¯Éñ¾ÔªÖ§ÅäµÄÏÂÖ«Ô˶¯¹¦ÄܵĻָ´Ô½ºÃ¡£ÕâÒ»½á¹ûÓëµòÍö·¢ÉúµÄ³öÏÖ¼°¸ß·åʱ¼äÓÐ×ÅÃÜÇеÄÁªÏµ£¬¸ù¾Ý¶ÔµòÍö·¢Éúʱ¼äµÄÑо¿£¬×÷ÕßÈÏΪ½ÏÔçÓ¦Óôٺìϸ°ûÉú³ÉËØ¿ÉÒÖÖÆ»òÕß×è¶ÏµòÍöÆô¶¯·¢ÉúµÄ·¾¶[19]£¬Ê¹µòÍöϸ°ûÊýÁ¿´ó´ó¼õÉÙ£¬´Ó¶ø½µµÍ¼Ì·¢ÐÔËðÉ˳̶ȡ£µòÍöÔÚËðÉ˺ó24~48 hÒÑ´ïµ½¸ß·åÆÚ£¬ÒÔºóÖð½¥Ï½µ£¬É˺ó7 dÈÔ´æÔÚ£¬ËùÒÔ24 h×éÓ¦Óôٺìϸ°ûÉú³ÉËØËäÈ»ÈÔÓÐЧ£¬µ«²»Èç1 hºÍ6 h×é¸üÃ÷ÏÔ¡£ÔÚÉ˺ó1£¬6£¬24 hÓ¦Óôٺìϸ°ûÉú³ÉËØ¾ùÓÐЧ˵Ã÷´Ùºìϸ°ûÉú³ÉËØµÄÓ¦Óô°¿Ú±È½Ï¿í£¬Õâ¸üÓÐÀûÓÚÁÙ´²ÉϵÄʵ¼ÊÓ¦Óá£
×ÛÉÏËùÊö, ÔçÆÚÓ¦ÓÃÍâÔ´ÐÔ´Ùºìϸ°ûÉú³ÉËØ¶Ô¼¹Ëè²»ÍêÈ«ËðÉ˺óÒýÆðµÄÉñ¾Ô˶¯¹¦ÄÜË𺦾ßÓб£»¤×÷ÓôËÖÖ±£»¤×÷ÓÃÓë´Ùºìϸ°ûÉú³ÉËØÄܹ»¼õÉÙÉñ¾Ï¸°ûµòÍöÓйء£µ«ÊÇÍâÔ´ÐÔ´Ùºìϸ°ûÉú³ÉËØÊÇÈçºÎÓë¼¹ËèÉñ¾Ï¸°û·¢Éú×÷Óã¬Í¨¹ýºÎÖÖÐźż¶ÁªÍ¾¾¶À´ÊµÏÖ¶ÔÉñ¾Ï¸°ûµòÍöÆô¶¯µÄÒÖÖÆ×÷ÓõÄÈÔÐè½øÒ»²½Ñо¿¡£¬¼
4 ²Î¿¼ÎÄÏ×
1 Ehrenreich H,Aust C,Krampe H, et al. Erythropoietin: novel approaches to neuroprotection in human brain disease. Metab Brain Dis 2004; 19:195-206
2 Leist M, Ghezzi P, Grasso G, et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004;305:239-242
3 Vitellaro-Zuccarello L, Mazzetti S, Madaschi L,et al. erythropoietin- mediated preservation of the white matter in rat spinal cord injury Neuroscience 2007;144:865-877
4 Zhang J, Li Y, Cui Y, Chen J, et al.Erythropoietin treatment improves neurological functional recovery in EAE mice. Brain Res 2005; 1034:34-39
5 Grasso G, Sfacteria A, Erbayraktar S, Amelioration of spinal cord compressive injury by pharmacological preconditioning with erythropoietin and a nonerythropoietic erythropoietin derivative. Neurosurg Spine 2006;4(4):310-318
6 Okutan O,Solaroglu I,Beskonakli E,et al. Recombinant human erythropoietin decreases myeloperoxidase and caspase-3 activity and improves early functional results after spinal cord injury in rats.Journal of Clinical Neuroscience 2007;14(4):364-368
7 Allen AR. Surgery of experimental lesion of spinal cord equivalent to crush injury of fracture dislocation of spinal column. A preliminary report.JAMA 1911;57:878-880
8 Nystrom B ,Berglund JE ,Bergquist E.Methodological analysis of an experimental spinal cord compression model in the rat.Acta Neurol Scand 1988;78(6):460 - 466
9 Basso DM, Beattie MS, Bresnahan JC. Graded histological and locomotor outcomes after spinal cord contusion using the NYU weight-drop device versus transection. Exp Neurol 1996;139:244-256
10 Sekhon LH, Fehlings MG. Epidemiology,demographics, and athophysiology of acute spinal cord injury. Spine 2001;26:S2-S12
11 Jacobs WB, Fehlings MG. The molecular basis of neural regeneration. Neurosurgery 2003;53:943-949
12 Stys PK.White matter injury mechanisms. Curr Mol 2004;4:113-130
13 Hasselblatt M, Ehrenreich H, Sir¨¦n AL. The Brain Erythropoietin System and its Potential forTherapeutic Exploitation in Brain Disease. Neurosurg Anesthesiol 2006;18:132-138
14 Celik M, Gokmen N, Erbayraktar S,et al. Erythropoietin prevents motor neuron apoptosis and meurologic disability in experimental spinal cord ischemic injury.PNAS 2002;99(4):2258-2263
15 Solaroglu I. Solaroglu A. Kaptanoglu E, et al. Erythropoietin prevents ischemia-reperfusion from inducing oxidative damage in fetal rat brain. Childs Nervous System 2003;19(1):19-22
16 Xiang S,Pan W,Kastin AJ. Strategies to create a regenerating environment for the injured spinal cord. [Review] Current Pharmaceutical Design 2005;11(10):1267-1277
17 Yune TY,Chang MJ,Kim SJ,et a1.Incresed production of tumor necrosis factor-alpha induces apoptosis after traumatic spinal cord injury in rats.Neurotrauma 2003;20:207-2l9
18 Liu XZ, Xu XM, Hu R, et al. Neuronal and glial apoptosis after traumatic spinal cord injury. Neurosci 1997;17:5395-406
19 Xu YJ,Liu YC,Zheng ZG.Zhonghua Chuangshang Zazhi 2004;20(7): 06-409
ÐìÓÖ¼Ñ,ÁõÑÞ³¬,֣׿¸ù.´óÊó¼¹ËèռλËðÉ˺óϸ°ûµòÍöÔÚ²»Í¬¼¹ËèÆ½Ãæ¡¢²»Í¬Ê±¼äµÄ±ä»¯¼°ÆäÒâÒå[J].Öлª´´ÉËÔÓÖ¾, 2004,20(7):406-409
20 Arishima Y, Setoguchi T, Yamaura I, et al.These findings suggest that exogenous erythropoietin decreases the number of apoptotic cells observed between the very early and subchronic stages following traumatic SCI. Spine 2006;31(21):2432-2438
21 Gorio A, Cokmen N, Erbayraktar S, et al. Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma.Proc Natl Acad Sci USA 2002;99(14):9450-9455
22 Ackerman WE 3rd, Ahmad M. The Efficacy of Lumbar Epidural Steroid Injections in Patients with Lumbar Disc Herniations.Anesth Analg 2007;104:1217-1222
23 Siren AL, Fratelli M, Brines M, et al. Erythropoietin prevent neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci U S A 2001;98:4044-4049
|